Effect of DASH diet in patients with non-alcoholic fatty liver disease

Phase 3

• Conditions: on-alcoholic fatty liver disease.; Non-alcoholic fatty liver disease; DB92.Y

• Registration Number: IRCT20170117032026N3
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. People 18 to 70 years old 2. People with body mass index 25 to 40 3. Diagnosis based on liver fibroscan 4. Have informed consent.

Exclusion Criteria

1. Pregnancy and lactation 2. Hereditary hemochromatosis 3. History of gingival or gastroplasty bypass surgery 4. Use of hepatotoxic drugs such as calcium channel blockers and high doses of synthetic estrogens 5. Patients with hypothyroidism 6. Cushing's syndrome and 7. Kidney failure Kidney stones 8. Cardiovascular disease 9. People with a history of hepatitis B and C 10. Wilson disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Alanine Aminotransferase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Aspartat transaminase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Gamma-glutamyl transpeptidase. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Special kits.;Hepatic fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;Hepatic steatosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.